Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edwin Pascal Alyea III, M.D.

Co-Author

This page shows the publications co-authored by Edwin Alyea and Philippe Armand.
Connection Strength

6.248
  1. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25.
    View in: PubMed
    Score: 0.428
  2. Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 Jun 11; 135(24):2182-2191.
    View in: PubMed
    Score: 0.249
  3. Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Rai SC, Armand P, Cutler CS, Ho VT, Glotzbecker B, Yusuf R, Nikiforow S, Chen YB, Dey B, McMasters M, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018 03; 103(3):522-530.
    View in: PubMed
    Score: 0.211
  4. Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2018 03; 24(3):514-520.
    View in: PubMed
    Score: 0.209
  5. Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE, Chen YB, Cutler CS, Ho VT, Koreth J, Kotwaliwale C, Nikiforow S, Ritz J, Rodig SJ, Soiffer RJ, Antin JH, Armand P. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016 Dec; 175(5):841-850.
    View in: PubMed
    Score: 0.193
  6. Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V, Devine SM, Waller EK, Jagirdar N, Herrera AF, Cutler C, Ho VT, Koreth J, Alyea EP, McAfee SL, Soiffer RJ, Chen YB, Antin JH. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016 Apr; 173(1):96-104.
    View in: PubMed
    Score: 0.183
  7. Koreth J, Kim HT, Lange PB, Bindra B, Reynolds CG, Chammas MJ, Armand P, Cutler CS, Ho VT, Glotzbecker B, Nikiforow S, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1907-13.
    View in: PubMed
    Score: 0.176
  8. Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, Glotzbecker B, Ho VT, Antin JH, Soiffer RJ, Ritz J, Alyea EP. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1516-21.
    View in: PubMed
    Score: 0.164
  9. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, Rizzo JD, Horowitz MM, Saber W. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014 Jun 05; 123(23):3664-71.
    View in: PubMed
    Score: 0.163
  10. Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Armand P. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1713-8.
    View in: PubMed
    Score: 0.157
  11. Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, Koreth J, Ritz J, Wu C, Antin JH, Soiffer RJ, Gribben JG, Alyea EP. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013 Feb; 27(2):362-9.
    View in: PubMed
    Score: 0.145
  12. Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, Ho VT, Cutler C, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Alyea EP. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012 Sep 10; 30(26):3202-8.
    View in: PubMed
    Score: 0.145
  13. Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Ritz J, Sorror ML, Lee SJ, Deeg HJ, Storer BE, Appelbaum FR, Antin JH, Soiffer RJ, Kim HT. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 Jul 26; 120(4):905-13.
    View in: PubMed
    Score: 0.143
  14. Armand P, Sainvil MM, Kim HT, Rhodes J, Cutler C, Ho VT, Koreth J, Alyea EP, Neufeld EJ, Kwong RY, Soiffer RJ, Antin JH. Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 2013 Jan; 48(1):146-7.
    View in: PubMed
    Score: 0.143
  15. Armand P, Sainvil MM, Kim HT, Rhodes J, Cutler C, Ho VT, Koreth J, Alyea EP, Neufeld EJ, Kwong RY, Soiffer RJ, Antin JH. Does iron overload really matter in stem cell transplantation? Am J Hematol. 2012 Jun; 87(6):569-72.
    View in: PubMed
    Score: 0.141
  16. Abou-Nassar KE, Kim HT, Blossom J, Ho VT, Soiffer RJ, Cutler CS, Alyea EP, Koreth J, Antin JH, Armand P. The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 May; 18(5):708-15.
    View in: PubMed
    Score: 0.136
  17. Ho VT, Kim HT, Aldridge J, Liney D, Kao G, Armand P, Koreth J, Cutler C, Ritz J, Antin JH, Soiffer RJ, Alyea EP. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1196-204.
    View in: PubMed
    Score: 0.129
  18. Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT, Koreth J, Alyea EP, Hearsey D, Neufeld EJ, Fleming MD, Steen H, Anderson D, Kwong RY, Soiffer RJ, Antin JH. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jun; 17(6):852-60.
    View in: PubMed
    Score: 0.127
  19. Armand P, Kim HT, Mayer E, Cutler CS, Ho VT, Koreth J, Alyea EP, Antin JH, Soiffer RJ. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant. 2010 Nov; 45(11):1611-7.
    View in: PubMed
    Score: 0.122
  20. Koreth J, Stevenson KE, Kim HT, Garcia M, Ho VT, Armand P, Cutler C, Ritz J, Antin JH, Soiffer RJ, Alyea EP. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009 Oct 29; 114(18):3956-9.
    View in: PubMed
    Score: 0.118
  21. Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, Antin JH, Soiffer RJ, Alyea EP. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009 Jul; 15(7):844-50.
    View in: PubMed
    Score: 0.117
  22. Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74.
    View in: PubMed
    Score: 0.112
  23. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Ritz J, Alyea EP, Antin JH, Soiffer RJ. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1):28-35.
    View in: PubMed
    Score: 0.104
  24. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, Ritz J, Alyea EP, Antin JH, Soiffer RJ. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64.
    View in: PubMed
    Score: 0.100
  25. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, Soiffer RJ, Antin JH. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007 May 15; 109(10):4586-8.
    View in: PubMed
    Score: 0.098
  26. Espada E, Cheng MP, Kim HT, Woolley AE, Avigan JI, Forcade E, Soares MVD, Lacerda JF, Nikiforow S, Gooptu M, Romee R, Alyea EP, Armand P, Cutler CS, Ho VT, Koreth J, Antin JH, Soiffer RJ, Marty FM, Ritz J. BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv. 2020 May 12; 4(9):1881-1893.
    View in: PubMed
    Score: 0.062
  27. Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, Ho VT. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Mar; 26(3):529-539.
    View in: PubMed
    Score: 0.060
  28. DeFilipp Z, Li S, Avigan D, Armand P, Ho VT, Koreth J, Nikiforow S, Alyea EP, Ritz J, Boussiotis V, Rosenblatt J, Brown J, McAfee S, Dey BR, El-Jawahri A, Spitzer TR, Chen YB, Soiffer RJ, Antin JH, Ballen KK, Cutler CS. A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 Apr; 55(4):804-810.
    View in: PubMed
    Score: 0.060
  29. Whangbo JS, Kim HT, Mirkovic N, Leonard L, Poryanda S, Silverstein S, Kim S, Reynolds CG, Rai SC, Verrill K, Lee MA, Margossian S, Duncan C, Lehmann L, Huang J, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Koreth J. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561.
    View in: PubMed
    Score: 0.059
  30. Belizaire R, Kim HT, Poryanda SJ, Mirkovic NV, Hipolito E, Savage WJ, Reynolds CG, Fields MJ, Whangbo J, Kubo T, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Ritz J, Soiffer RJ, Koreth J. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):969-979.
    View in: PubMed
    Score: 0.057
  31. Whangbo JS, Kim HT, Nikiforow S, Koreth J, Alho AC, Falahee B, Kim S, Dusenbury K, Fields MJ, Reynolds CG, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Ritz J. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):984-994.
    View in: PubMed
    Score: 0.057
  32. Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):137-144.
    View in: PubMed
    Score: 0.055
  33. Postalcioglu M, Kim HT, Obut F, Yilmam OA, Yang J, Byun BC, Kupiec-Weglinski S, Soiffer R, Ritz J, Antin JH, Alyea E, Koreth J, Cutler C, Armand P, Paik JM, Leaf DE, Ho VT, Abdi R. Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2344-2353.
    View in: PubMed
    Score: 0.054
  34. Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, Ritz J, Nikiforow S, Glotzbecker BE, Nageshwar P, Soiffer RJ, Antin JH, Cutler CS. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018 08; 24(8):1733-1740.
    View in: PubMed
    Score: 0.053
  35. Wang KS, Kim HT, Nikiforow S, Heubeck AT, Ho VT, Koreth J, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Cutler CS, Ritz J. Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood. 2017 12 28; 130(26):2889-2899.
    View in: PubMed
    Score: 0.052
  36. Kekre N, Kim HT, Ho VT, Cutler C, Armand P, Nikiforow S, Alyea EP, Soiffer RJ, Antin JH, Connors JM, Koreth J. Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2017 07; 102(7):1185-1191.
    View in: PubMed
    Score: 0.050
  37. Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita H, Koreth J, Kim HT, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Maeda Y, Tanimoto M, Ritz J, Matsuoka KI. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017 04 13; 129(15):2186-2197.
    View in: PubMed
    Score: 0.049
  38. Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J, Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
    View in: PubMed
    Score: 0.049
  39. Nikiforow S, Li S, Snow K, Liney D, Kao GS, Haspel R, Shpall EJ, Glotzbecker B, Sica RA, Armand P, Koreth J, Ho VT, Alyea EP, Ritz J, Soiffer RJ, Antin JH, Dey B, McAfee S, Chen YB, Spitzer T, Avigan D, Cutler CS, Ballen K. Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
    View in: PubMed
    Score: 0.049
  40. Hirakawa M, Matos TR, Liu H, Koreth J, Kim HT, Paul NE, Murase K, Whangbo J, Alho AC, Nikiforow S, Cutler C, Ho VT, Armand P, Alyea EP, Antin JH, Blazar BR, Lacerda JF, Soiffer RJ, Ritz J. Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016 11 03; 1(18):e89278.
    View in: PubMed
    Score: 0.049
  41. Treister N, Li S, Kim H, Lerman M, Sultan A, Alyea EP, Armand P, Cutler C, Ho V, Koreth J, Antin JH, Soiffer R. An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016 11; 22(11):2084-2091.
    View in: PubMed
    Score: 0.048
  42. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
    View in: PubMed
    Score: 0.048
  43. Nikiforow S, Kim HT, Daley H, Reynolds C, Jones KT, Armand P, Ho VT, Alyea EP, Cutler CS, Ritz J, Antin JH, Soiffer RJ, Koreth J. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. 2016 10; 101(10):1251-1259.
    View in: PubMed
    Score: 0.047
  44. Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, Dusenbury K, Whangbo J, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Chen YB, Avigan D, Blazar BR, Antin JH, Ritz J, Soiffer RJ. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7.
    View in: PubMed
    Score: 0.047
  45. Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, Ho VT, Koreth J, Armand P, Alyea EP, Blazar BR, Soiffer RJ, Antin JH, Ritz J. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016 05 19; 127(20):2489-97.
    View in: PubMed
    Score: 0.046
  46. Martin PS, Li S, Nikiforow S, Alyea EP, Antin JH, Armand P, Cutler CS, Ho VT, Kekre N, Koreth J, Luckey CJ, Ritz J, Soiffer RJ. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016 Apr; 101(4):499-505.
    View in: PubMed
    Score: 0.046
  47. El-Jawahri A, Li S, Antin JH, Spitzer TR, Armand PA, Koreth J, Nikiforow S, Ballen KK, Ho VT, Alyea EP, Dey BR, McAfee SL, Glotzbecker BE, Soiffer RJ, Cutler CS, Chen YB. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016 May; 22(5):910-8.
    View in: PubMed
    Score: 0.046
  48. Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, Whangbo J, Nikiforow S, Cutler CS, Koreth J, Ho VT, Armand P, Antin JH, Alyea EP, Lacerda JF, Soiffer RJ, Ritz J. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016 Feb 04; 127(5):646-57.
    View in: PubMed
    Score: 0.046
  49. Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler C, Nikiforow S, Ho VT, Koreth J, Alyea EP, Soiffer RJ. Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep; 100(9):1222-7.
    View in: PubMed
    Score: 0.044
  50. Kim HT, Armand P, Frederick D, Andler E, Cutler C, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Ritz J, Ho VT. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant. 2015 May; 21(5):873-80.
    View in: PubMed
    Score: 0.043
  51. Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, Antin JH, Alyea E, Armand P, Ho V, Koreth J, Neuberg D, Cutler CS, Ebert BL. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
    View in: PubMed
    Score: 0.042
  52. Herrera AF, Kim HT, Bindra B, Jones KT, Alyea EP, Armand P, Cutler CS, Ho VT, Nikiforow S, Blazar BR, Ritz J, Antin JH, Soiffer RJ, Koreth J. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1737-43.
    View in: PubMed
    Score: 0.041
  53. Murase K, Kim HT, Bascug OR, Kawano Y, Ryan J, Matsuoka K, Davids MS, Koreth J, Ho VT, Cutler C, Armand P, Alyea EP, Blazar BR, Antin JH, Soiffer RJ, Letai A, Ritz J. Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508.
    View in: PubMed
    Score: 0.041
  54. Kim HT, Frederick D, Armand P, Andler E, Kao G, Cutler C, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Ritz J, Ho VT. White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol. 2014 Jun; 89(6):591-7.
    View in: PubMed
    Score: 0.040
  55. Jacobson CA, Sun L, Kim HT, McDonough SM, Reynolds CG, Schowalter M, Koreth J, Cutler CS, Ho VT, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Ritz J, Sarantopoulos S. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 May; 20(5):668-75.
    View in: PubMed
    Score: 0.040
  56. Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J, Pelus LM, Desponts C, Chen YB, Rezner B, Armand P, Koreth J, Glotzbecker B, Ho VT, Alyea E, Isom M, Kao G, Armant M, Silberstein L, Hu P, Soiffer RJ, Scadden DT, Ritz J, Goessling W, North TE, Mendlein J, Ballen K, Zon LI, Antin JH, Shoemaker DD. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013 Oct 24; 122(17):3074-81.
    View in: PubMed
    Score: 0.039
  57. Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
    View in: PubMed
    Score: 0.039
  58. Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, Rosenblatt J, McDonough S, Watanaboonyongcharoen P, Armand P, Koreth J, Glotzbecker B, Alyea E, Blazar BR, Soiffer RJ, Ritz J, Antin JH. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013 Aug 22; 122(8):1510-7.
    View in: PubMed
    Score: 0.039
  59. Brunner AM, Kim HT, Coughlin E, Alyea EP, Armand P, Ballen KK, Cutler C, Dey BR, Glotzbecker B, Koreth J, McAfee SL, Spitzer TR, Soiffer RJ, Antin JH, Ho VT, Chen YB. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1374-80.
    View in: PubMed
    Score: 0.038
  60. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, Armand P, Blazar BR, Antin JH, Soiffer RJ, Ritz J. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 03; 5(179):179ra43.
    View in: PubMed
    Score: 0.038
  61. Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jun; 19(6):981-7.
    View in: PubMed
    Score: 0.038
  62. Nikiforow S, Kim HT, Bindra B, McDonough S, Glotzbecker B, Armand P, Koreth J, Ho VT, Alyea EP, Blazar BR, Ritz J, Soiffer RJ, Antin JH, Cutler CS. Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013 May; 19(5):804-11.
    View in: PubMed
    Score: 0.037
  63. Garfall A, Kim HT, Sun L, Ho VT, Armand P, Koreth J, Alyea EP, Soiffer RJ, Antin JH, Ritz J, Cutler C. KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. Bone Marrow Transplant. 2013 Jul; 48(7):1000-2.
    View in: PubMed
    Score: 0.037
  64. Hill JA, Koo S, Guzman Suarez BB, Ho VT, Cutler C, Koreth J, Armand P, Alyea EP, Baden LR, Antin JH, Soiffer RJ, Marty FM. Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1638-48.
    View in: PubMed
    Score: 0.036
  65. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66.
    View in: PubMed
    Score: 0.034
  66. Chen YB, Aldridge J, Kim HT, Ballen KK, Cutler C, Kao G, Liney D, Bourdeau G, Alyea EP, Armand P, Koreth J, Ritz J, Spitzer TR, Soiffer RJ, Antin JH, Ho VT. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012 May; 18(5):805-12.
    View in: PubMed
    Score: 0.034
  67. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, Koreth J, Ho V, Alyea E, Ballen K, Ritz J, Soiffer RJ, Milford E, Antin JH. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011 Dec 15; 118(25):6691-7.
    View in: PubMed
    Score: 0.034
  68. Jacobson CA, Turki AT, McDonough SM, Stevenson KE, Kim HT, Kao G, Herrera MI, Reynolds CG, Alyea EP, Ho VT, Koreth J, Armand P, Chen YB, Ballen K, Soiffer RJ, Antin JH, Cutler CS, Ritz J. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):565-74.
    View in: PubMed
    Score: 0.034
  69. Blaser BW, Kim HT, Alyea EP, Ho VT, Cutler C, Armand P, Koreth J, Antin JH, Plutzky J, Soiffer RJ. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):575-83.
    View in: PubMed
    Score: 0.034
  70. Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, Armand P, Alyea EP, Freedman AS, Soiffer RJ, Antin JH. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011 Jul; 22(7):1608-13.
    View in: PubMed
    Score: 0.032
  71. Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP, Cutler CS, Koreth J, Armand P, Ho VT, Antin JH, Soiffer RJ, Baden LR. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Mar; 17(3):434-8.
    View in: PubMed
    Score: 0.032
  72. Koreth J, Biernacki M, Aldridge J, Kim HT, Alyea EP, Armand P, Cutler C, Ho VT, Wu CJ, Antin JH, Soiffer RJ. Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):421-8.
    View in: PubMed
    Score: 0.032
  73. Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, Reynolds C, Liney D, Kao G, Ho V, Armand P, Koreth J, Alyea E, Dey BR, Attar E, Spitzer T, Boussiotis VA, Ritz J, Soiffer R, Antin JH, Ballen K. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011 May; 46(5):659-67.
    View in: PubMed
    Score: 0.031
  74. Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, Ho V, Alyea E, Koreth J, Armand P, Soiffer R, Ritz J, Richardson PG, Antin JH. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1180-5.
    View in: PubMed
    Score: 0.031
  75. Brown JA, Stevenson K, Kim HT, Cutler C, Ballen K, McDonough S, Reynolds C, Herrera M, Liney D, Ho V, Kao G, Armand P, Koreth J, Alyea E, McAfee S, Attar E, Dey B, Spitzer T, Soiffer R, Ritz J, Antin JH, Boussiotis VA. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9.
    View in: PubMed
    Score: 0.030
  76. Koreth J, Aldridge J, Kim HT, Alyea EP, Cutler C, Armand P, Ritz J, Antin JH, Soiffer RJ, Ho VT. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010 Jun; 16(6):792-800.
    View in: PubMed
    Score: 0.030
  77. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 01; 112(12):4425-31.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.